Caregen Co., Ltd. (KOSDAQ:214370)
South Korea · Delayed Price · Currency is KRW | Market Cap | 5.16T +305.8% |
| Revenue (ttm) | 72.81B -11.8% |
| Net Income | 20.10B -37.8% |
| EPS | 411.00 -37.5% |
| Shares Out | 48.87M |
| PE Ratio | 256.69 |
| Forward PE | n/a |
| Dividend | 640.00 (0.60%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 152,837 |
| Average Volume | 158,446 |
| Open | 103,900 |
| Previous Close | 106,000 |
| Day's Range | 101,000 - 110,000 |
| 52-Week Range | 22,750 - 153,800 |
| Beta | 1.20 |
| RSI | 53.33 |
| Earnings Date | Apr 30, 2026 |
About Caregen
Caregen Co., Ltd., a biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. The company offers filler products under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names; skin care products under the Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert names; scalp care products under the Renokin and Pelo Baum names; and healthy foods under the proGsterol name. It is also developing medicines for COVID-19 treatment, wet macular degeneration, dry macular degeneration, antivira... [Read more]
Financial Performance
In 2025, Caregen's revenue was 72.81 billion, a decrease of -11.84% compared to the previous year's 82.59 billion. Earnings were 20.10 billion, a decrease of -37.80%.
Financial StatementsNews
Akums Drugs shares surge 5% after signing Master Sales Agreement with Caregen
Akums Drugs and Pharmaceuticals saw a 5% jump in its stock price after signing an exclusive Master Sales Agreement with South Korea-based Caregen Co., Ltd. The deal gives Akums exclusive rights to pac...
Akums Drugs signs Master Sales Agreement with Caregen for Indian Nutraceutical market expansion
Akums Drugs and Pharmaceuticals Ltd., a leading name in the pharmaceutical industry, has signed an exclusive Master Sales Agreement with South Korea’s Caregen Co., Ltd. This partnership grants Akums e...